147,654 Shares in Fulcrum Therapeutics, Inc. $FULC Acquired by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 147,654 shares of the company’s stock, valued at approximately $425,000. Jacobs Levy Equity Management Inc. owned about 0.27% of Fulcrum Therapeutics at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $38,000. Jump Financial LLC bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth approximately $30,000. Brooklyn Investment Group grew its position in shares of Fulcrum Therapeutics by 209.7% in the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after buying an additional 8,254 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth approximately $39,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth approximately $92,000. 89.83% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Leerink Partnrs upgraded Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 23rd. HC Wainwright upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $4.00 to $12.00 in a research report on Tuesday, July 29th. Royal Bank Of Canada lifted their price objective on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a research report on Wednesday, July 30th. Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Finally, Leerink Partners upgraded Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $9.60.

Fulcrum Therapeutics Stock Up 0.1%

NASDAQ FULC opened at $7.00 on Friday. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $8.50. The firm has a market capitalization of $378.63 million, a PE ratio of -5.74 and a beta of 2.82. The stock’s 50 day moving average is $7.08 and its 200 day moving average is $5.59.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. On average, research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.